Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin
de Haan, Willeke × de Vries-van der Weij, Jitske van der Hoorn, José W A Gautier, Thomas van der Hoogt, Caroline C Westerterp, Marit Romijn, Johannes A Jukema, J Wouter Havekes, Louis M Princen, Hans M G Rensen, Patrick C N #
Lippincott Williams & Wilkins
Circulation vol:117 issue:19 pages:2515-22
Although cholesteryl ester transfer protein (CETP) inhibition is regarded as a promising strategy to reduce atherosclerosis by increasing high-density lipoprotein cholesterol, the CETP inhibitor torcetrapib given in addition to atorvastatin had no effect on atherosclerosis and even increased cardiovascular death in the recent Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial. Therefore, we evaluated the antiatherogenic potential and adverse effects of torcetrapib in humanized APOE*3-Leiden.CETP (E3L.CETP) mice.